123 related articles for article (PubMed ID: 15300809)
1. Identification of a small peptide that inhibits the phosphorylation of ErbB2 and proliferation of ErbB2 overexpressing breast cancer cells.
Pero SC; Shukla GS; Armstrong AL; Peterson D; Fuller SP; Godin K; Kingsley-Richards SL; Weaver DL; Bond J; Krag DN
Int J Cancer; 2004 Oct; 111(6):951-60. PubMed ID: 15300809
[TBL] [Abstract][Full Text] [Related]
2. Phage-displayed combinatorial peptide libraries in fusion to beta-lactamase as reporter for an accelerated clone screening: Potential uses of selected enzyme-linked affinity reagents in downstream applications.
Shukla GS; Krag DN
Comb Chem High Throughput Screen; 2010 Jan; 13(1):75-87. PubMed ID: 20214576
[TBL] [Abstract][Full Text] [Related]
3. Identification of novel non-phosphorylated ligands, which bind selectively to the SH2 domain of Grb7.
Pero SC; Oligino L; Daly RJ; Soden AL; Liu C; Roller PP; Li P; Krag DN
J Biol Chem; 2002 Apr; 277(14):11918-26. PubMed ID: 11809769
[TBL] [Abstract][Full Text] [Related]
4. Selective inhibition of ErbB2-overexpressing breast cancer in vivo by a novel TAT-based ErbB2-targeting signal transducers and activators of transcription 3-blocking peptide.
Tan M; Lan KH; Yao J; Lu CH; Sun M; Neal CL; Lu J; Yu D
Cancer Res; 2006 Apr; 66(7):3764-72. PubMed ID: 16585203
[TBL] [Abstract][Full Text] [Related]
5. Peptide aptamers with binding specificity for the intracellular domain of the ErbB2 receptor interfere with AKT signaling and sensitize breast cancer cells to Taxol.
Kunz C; Borghouts C; Buerger C; Groner B
Mol Cancer Res; 2006 Dec; 4(12):983-98. PubMed ID: 17189388
[TBL] [Abstract][Full Text] [Related]
6. Design and synthesis of paclitaxel conjugated with an ErbB2-recognizing peptide, EC-1.
Li P; Jiang S; Pero SC; Oligino L; Krag DN; Michejda CJ; Roller PP
Biopolymers; 2007 Nov; 87(4):225-30. PubMed ID: 17879382
[TBL] [Abstract][Full Text] [Related]
7. Phage display selection for cell-specific ligands: development of a screening procedure suitable for small tumor specimens.
Shukla GS; Krag DN
J Drug Target; 2005 Jan; 13(1):7-18. PubMed ID: 15848950
[TBL] [Abstract][Full Text] [Related]
8. Epidermal growth factor receptor coexpression modulates susceptibility to Herceptin in HER2/neu overexpressing breast cancer cells via specific erbB-receptor interaction and activation.
Diermeier S; Horváth G; Knuechel-Clarke R; Hofstaedter F; Szöllosi J; Brockhoff G
Exp Cell Res; 2005 Apr; 304(2):604-19. PubMed ID: 15748904
[TBL] [Abstract][Full Text] [Related]
9. Selection of tumor-specific internalizing human antibodies from phage libraries.
Poul MA; Becerril B; Nielsen UB; Morisson P; Marks JD
J Mol Biol; 2000 Sep; 301(5):1149-61. PubMed ID: 10966812
[TBL] [Abstract][Full Text] [Related]
10. PC cell-derived growth factor stimulates proliferation and confers Trastuzumab resistance to Her-2-overexpressing breast cancer cells.
Kim WE; Serrero G
Clin Cancer Res; 2006 Jul; 12(14 Pt 1):4192-9. PubMed ID: 16857791
[TBL] [Abstract][Full Text] [Related]
11. Cell type dependent endocytic internalization of ErbB2 with an artificial peptide ligand that binds to ErbB2.
Hashizume T; Fukuda T; Nagaoka T; Tada H; Yamada H; Watanabe K; Salomon DS; Seno M
Cell Biol Int; 2008 Jul; 32(7):814-26. PubMed ID: 18442934
[TBL] [Abstract][Full Text] [Related]
12. Identification of natural ligands for SH2 domains from a phage display cDNA library.
Cochrane D; Webster C; Masih G; McCafferty J
J Mol Biol; 2000 Mar; 297(1):89-97. PubMed ID: 10704309
[TBL] [Abstract][Full Text] [Related]
13. Selection of tumor-targeting agents on freshly excised human breast tumors using a phage display library.
Shukla GS; Krag DN
Oncol Rep; 2005 Apr; 13(4):757-64. PubMed ID: 15756454
[TBL] [Abstract][Full Text] [Related]
14. Screening and Identification of Peptides Specifically Targeted to Gastric Cancer Cells from a Phage Display Peptide Library.
Sahin D; Taflan SO; Yartas G; Ashktorab H; Smoot DT
Asian Pac J Cancer Prev; 2018 Apr; 19(4):927-932. PubMed ID: 29693344
[TBL] [Abstract][Full Text] [Related]
15. The ErbB/HER family of protein-tyrosine kinases and cancer.
Roskoski R
Pharmacol Res; 2014 Jan; 79():34-74. PubMed ID: 24269963
[TBL] [Abstract][Full Text] [Related]
16. A combination of in vitro techniques for efficient discovery of functional monoclonal antibodies against human CXC chemokine receptor-2 (CXCR2).
Boshuizen RS; Marsden C; Turkstra J; Rossant CJ; Slootstra J; Copley C; Schwamborn K
MAbs; 2014; 6(6):1415-24. PubMed ID: 25484047
[TBL] [Abstract][Full Text] [Related]
17. Heregulin and agonistic anti-p185(c-erbB2) antibodies inhibit proliferation but increase invasiveness of breast cancer cells that overexpress p185(c-erbB2): increased invasiveness may contribute to poor prognosis.
Xu FJ; Stack S; Boyer C; O'Briant K; Whitaker R; Mills GB; Yu YH; Bast RC
Clin Cancer Res; 1997 Sep; 3(9):1629-34. PubMed ID: 9815853
[TBL] [Abstract][Full Text] [Related]
18. Single-chain antibody-mediated gene delivery into ErbB2-positive human breast cancer cells.
Li X; Stuckert P; Bosch I; Marks JD; Marasco WA
Cancer Gene Ther; 2001 Aug; 8(8):555-65. PubMed ID: 11571533
[TBL] [Abstract][Full Text] [Related]
19. Hsp90 inhibitor 17-AAG reduces ErbB2 levels and inhibits proliferation of the trastuzumab resistant breast tumor cell line JIMT-1.
Zsebik B; Citri A; Isola J; Yarden Y; Szöllosi J; Vereb G
Immunol Lett; 2006 Apr; 104(1-2):146-55. PubMed ID: 16384610
[TBL] [Abstract][Full Text] [Related]
20. The ErbB2/Neu/HER2 receptor is a new calmodulin-binding protein.
Li H; Sánchez-Torres J; Del Carpio A; Salas V; Villalobo A
Biochem J; 2004 Jul; 381(Pt 1):257-66. PubMed ID: 15080792
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
